Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Circassia paying £188m for two asthma firms, but it's still an allergy specialist

This article was originally published in Scrip

Executive Summary

Circassia is acquiring two asthma product developers for more than £188m but this doesn't mean the company is dropping its allergy focus.

You may also be interested in...



Mite Trial Failure 'The Final Straw' As Circassia Ends Anti-Allergy Investing

Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.

KO’d By Allergy Failure, Circassia Looks To Respiratory Pipeline For Second Wind

Circassia is shifting its focus on its respiratory portfolio following the disappointing Phase III results of its cat allergy drug in June, which saw the company’s share price plummet by more than 60%.

Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop

The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC028728

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel